FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paal Brunsvig

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Paal Brunsvig; Gustav Gaudernack; Gaute L Hansen; Christian Kersten; Jon Amund Kyte; Mona Møller; Marta Nyakas; Stein Sundstrøm; Steinar Aamdal
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Bjørn H Grønberg; Roy M Bremnes; Oystein Fløtten; Tore Amundsen; Paal Brunsvig; Harald H Hjelde; Stein Kaasa; Christian von Plessen; Frøydis Stornes; Terje Tollåli; Finn Wammer; Ulf Aasebø; Stein Sundstrøm
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Bjørn H Grønberg; Roy M Bremnes; Ulf Aasebø; Paal Brunsvig; Oystein Fløtten; Tore Amundsen; Christian von Plessen; Mari Wang; Stein Sundstrøm
A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paal Brunsvig (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Paal Brunsvig; Gustav Gaudernack; Gaute L Hansen; Christian Kersten; Jon Amund Kyte; Mona Møller; Marta Nyakas; Stein Sundstrøm; Steinar Aamdal
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6847-57.
2009: Bjørn H Grønberg; Roy M Bremnes; Oystein Fløtten; Tore Amundsen; Paal Brunsvig; Harald H Hjelde; Stein Kaasa; Christian von Plessen; Frøydis Stornes; Terje Tollåli; Finn Wammer; Ulf Aasebø; Stein Sundstrøm
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3217-24.
2009: Bjørn H Grønberg; Roy M Bremnes; Ulf Aasebø; Paal Brunsvig; Oystein Fløtten; Tore Amundsen; Christian von Plessen; Mari Wang; Stein Sundstrøm
A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2009;63(1):88-93.
2008: Serge Leyvraz; Sandro Pampallona; Giovanni Martinelli; Ferdinand Ploner; Lucien Perey; Savina Aversa; Solange Peters; Paal Brunsvig; Ana Montes; Andrzej Lange; Ugur Yilmaz; Giovanni Rosti
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Journal of the National Cancer Institute 2008;100(8):533-41.
2006: Stein Sundstrøm; Roy M Bremnes; Paal Brunsvig; Ulf Aasebø; Stein Kaasa
Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy?
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(8):816-24.
2005: Stein Sundstrøm; Roy M Bremnes; Paal Brunsvig; Ulf Aasebø; Klepp Olbjørn; Peter M Fayers; Stein Kaasa
Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;75(2):141-8.
2004: Stein Sundstrøm; Roy M Bremnes; Ulf Aasebø; Steinar Aamdal; Reidulv Hatlevoll; Paal Brunsvig; Dag Clement Johannessen; Olbjørn Klepp; Peter M Fayers; Stein Kaasa
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):801-10.